About Immuneering Corporation
https://immuneering.comImmuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors.
CEO
Benjamin J. Zeskind
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 32
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
FMR LLC
Shares:8.79M
Value:$38.93M
SANOFI
Shares:2.71M
Value:$12M
VANGUARD GROUP INC
Shares:2.42M
Value:$10.7M
Summary
Showing Top 3 of 71
About Immuneering Corporation
https://immuneering.comImmuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $15.29M ▲ | $-14.96M ▼ | 0% | $-0.38 ▲ | $-14.88M ▼ |
| Q2-2025 | $0 | $14.76M ▼ | $-14.43M ▲ | 0% | $-0.4 ▲ | $-14.67M ▲ |
| Q1-2025 | $0 | $15.48M ▼ | $-15.05M ▲ | 0% | $-0.42 ▲ | $-15.39M ▲ |
| Q4-2024 | $0 | $18.38M ▲ | $-18.05M ▼ | 0% | $-0.58 ▼ | $-17.88M ▼ |
| Q3-2024 | $0 | $15.27M | $-14.6M | 0% | $-0.49 | $-15.18M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $227.56M ▲ | $241.06M ▲ | $13.08M ▲ | $227.98M ▲ |
| Q2-2025 | $26.36M ▼ | $40.06M ▼ | $11.12M ▲ | $28.94M ▼ |
| Q1-2025 | $35.87M ▼ | $50.68M ▼ | $8.84M ▼ | $41.84M ▲ |
| Q4-2024 | $36.14M ▼ | $52.71M ▼ | $11.33M ▲ | $41.39M ▼ |
| Q3-2024 | $50.66M | $68.56M | $10.84M | $57.72M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-14.96M ▼ | $-11.98M ▼ | $-7.25K ▼ | $213.19M ▲ | $201.21M ▲ | $-11.98M ▼ |
| Q2-2025 | $-14.43M ▲ | $-9.45M ▲ | $-2.12K ▲ | $-61.96K ▼ | $-9.51M ▼ | $-9.45M ▲ |
| Q1-2025 | $-15.05M ▲ | $-14.08M ▲ | $-8.95K ▼ | $13.81M ▲ | $-279.02K ▲ | $-14.09M ▲ |
| Q4-2024 | $-18.05M ▼ | $-14.51M ▼ | $5.49M ▲ | $-40.99K ▼ | $-9.06M ▲ | $-14.52M ▼ |
| Q3-2024 | $-14.6M | $-13.47M | $-5.42M | $4.36M | $-14.52M | $-13.48M |
CEO
Benjamin J. Zeskind
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 32
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
FMR LLC
Shares:8.79M
Value:$38.93M
SANOFI
Shares:2.71M
Value:$12M
VANGUARD GROUP INC
Shares:2.42M
Value:$10.7M
Summary
Showing Top 3 of 71